Life Sciences Law360 provides breaking legal news and analysis on the
pharmaceutical and medical device industry. Coverage includes high-stakes
litigation and policy developments that affect life sciences companies, as well
as licensing deals, mergers, and other corporate transactions.
Sign up for a 7-day FREE trial today!
Latest News in Life Sciences
-
June 05, 2026
A retired New York Mercantile Exchange trader is charged with insider trading by securities regulators who allege he bought shares of Sanofi's biopharmaceutical unit Kadmon Holdings Inc. based on confidential information the trader received about Kadmon's flagship chronic graft-versus-host disease treatment drug in July 2021, and that the trader tipped off a friend about the information.
-
June 05, 2026
The Judicial Panel on Multidistrict Litigation declined to consolidate dozens of product liability cases over spinal cord stimulator devices manufactured by Boston Scientific Corp., Abbott Laboratories, Nevro and Medtronic, finding Friday that while centralization of the actions against Boston Scientific was appropriate, an industrywide action was not.
-
June 05, 2026
Transgender adolescents urged a California federal judge Friday to block a Stanford Medicine hospital from sharing gender-related care medical records in response to a Texas grand jury criminal subpoena, arguing that other courts have rebuffed similar government subpoena attempts and the judge should end the DOJ's "campaign of harassment."
-
June 05, 2026
A Los Angeles jury cleared Johnson & Johnson of any liability in the deaths of three women from ovarian cancer, finding Friday following a six-week bellwether trial that the company's sales of talcum powder were not negligent.
-
June 05, 2026
IRhythm Technologies Inc. investors asked a California federal judge to preliminarily greenlight a $45 million settlement resolving allegations the digital healthcare company inflated stock prices with misrepresentations about its heart-event monitoring device, noting the deal is a favorable result that warrants approval, given the possibility of no recovery.
See more Life Sciences news